KD Logo

A Guide To The Risks Of Investing In BioXcel Therapeutics Inc (BTAI)

In a filing, BioXcel Therapeutics Inc revealed its CEO and President Mehta Vimal unloaded Company’s shares for reported $2739.0 on Jun 17 ’24. In the deal valued at $1.28 per share,2,134 shares were sold. As a result of this transaction, Mehta Vimal now holds 47,539 shares worth roughly $49915.950000000004.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Yocca Frank sold 372 shares, generating $476 in total proceeds. Upon selling the shares at $1.28, the Chief Scientific Officer now owns 13,474 shares.

Before that, Steinhart Richard I sold 372 shares. BioXcel Therapeutics Inc shares valued at $470 were divested by the Chief Financial Officer at a price of $1.26 per share. As a result of the transaction, Steinhart Richard I now holds 5,476 shares, worth roughly $5749.8.

UBS downgraded its BioXcel Therapeutics Inc [BTAI] rating to a Neutral from a a Buy in a research note published on February 21, 2024; the price target was decreased to $4 from $9. A number of analysts have revised their coverage, including Mizuho’s analysts, who decreased its forecast for the stock in mid August from “a Buy” to “a Neutral”. Guggenheim also remained covering BTAI and has decreased its forecast on July 17, 2023 with a “Neutral” recommendation from previously “Buy” rating. Jefferies revised its rating on March 10, 2023. It rated BTAI as “a Hold” which previously was an “a Buy”.

Price Performance Review of BTAI

On Friday, BioXcel Therapeutics Inc [NASDAQ:BTAI] saw its stock fall -2.78% to $1.05. Over the last five days, the stock has lost -17.32%. BioXcel Therapeutics Inc shares have fallen nearly -64.41% since the year began. Nevertheless, the stocks have fallen -90.63% over the past one year. While a 52-week high of $12.40 was reached on 02/06/24, a 52-week low of $1.06 was recorded on 07/05/24. SMA at 50 days reached $1.8021, while 200 days put it at $2.8120. A total of 0.53 million shares were traded, compared to the trading of 0.43 million shares in the previous session.

Levels Of Support And Resistance For BTAI Stock

The 24-hour chart illustrates a support level at 1.0167, which if violated will result in even more drops to 0.9833. On the upside, there is a resistance level at 1.1017. A further resistance level may holdings at 1.1533. The Relative Strength Index (RSI) on the 14-day chart is 24.77, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1210, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.20%. Stochastics%K at 3.55% indicates the stock is a buying.

Most Popular